Harmony Biosciences Holdings (HRMY) Depreciation & Amortization (CF) (2019 - 2026)
Harmony Biosciences Holdings (HRMY) reported Depreciation & Amortization (CF) of $7000.0 for Q1 2026, little changed on a YoY basis from $7000.0 in Q1 2025, and little changed sequentially from $7000.0 in Q3 2025.
Harmony Biosciences Holdings (HRMY) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings (HRMY) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $7000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $7000.0; the trailing twelve-month figure through Mar 2026 stood at $20000.0 (down 81.98% YoY), and the FY2024 full-year result was $267000.0, down 48.05% from the prior year.
- Depreciation & Amortization (CF) was little changed at $7000.0 in Q1 2026, from $7000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $164000.0 in Q4 2023 to a low of $6000.0 in Q4 2024.
- A 5-year average of $76687.5 and a median of $97500.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Peak annual rise in Depreciation & Amortization (CF) reached 58.25% in 2024, while the deepest fall reached 96.34% in 2024.
- Tracing HRMY's Depreciation & Amortization (CF) over 5 years: stood at $107000.0 in 2022, then surged by 53.27% to $164000.0 in 2023, then plunged by 96.34% to $6000.0 in 2024, then climbed by 16.67% to $7000.0 in 2025, then changed by 0.0% to $7000.0 in 2026.
- Business Quant data shows HRMY's Depreciation & Amortization (CF) at $7000.0 in Q1 2026, $7000.0 in Q3 2025, and $6000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Harmony Biosciences Holdings | 2.07 Bn | 1.55 Bn | 170.88 Mn | 7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,000.00 |
| Mar 31, 2026 | 7,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Mar 31, 2024 | 163,000.00 |
| Mar 31, 2024 | 163,000.00 |
| Dec 31, 2023 | 164,000.00 |
| Dec 31, 2023 | 164,000.00 |
| Sep 30, 2023 | 144,000.00 |
| Sep 30, 2023 | 144,000.00 |